{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:18:48Z","timestamp":1787840328219,"version":"build-2784847793"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Molecular subtyping of urothelial cancer of the bladder can help in identifying aggressive subtypes and aid in the prognostication of the disease. These subtypes can be broadly identified with the help of immunohistochemistry (IHC) markers reliably.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To assess the molecular subtypes of urothelial carcinoma of the bladder using IHC markers and evaluate their association with clinicopathological characteristics and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This was a cross-sectional study done over 3 years in a tertiary care center. There were 109 cases of invasive urothelial carcinoma of the bladder. In 43 cases, radical cystectomy was performed, and 66 cases underwent transurethral resection of bladder tumor. CK5\/6, and CK14 were used as markers of the basal subtype; GATA-3 and CK20 were used for the luminal subtype. Cases were classified into basal, luminal, double-positive, and double-negative subtypes. The association of molecular subtypes with clinicopathological characteristics was analyzed. OS was analyzed for the molecular subtypes. All the relevant statistical tests were performed using IBM SPSS software version 24.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The most frequently occurring molecular subtype was luminal (GATA3+, CK5\/6\u2212) in 62% of cases. Tumors with the basal subtype showed a higher frequency of muscle invasion compared to nonbasal types and presented as high-grade tumors. The luminal subtype was significantly associated with conventional histology and lamina propria invasive tumors. The basal molecular subtype showed a mean OS of 15 (\u00b14) months, which was significantly worse than that of nonbasal subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The basal subtype of urothelial carcinoma of the bladder behaves more aggressively in terms of grade, extent of invasion, and OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpm.ijpm_290_25","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T16:01:00Z","timestamp":1755532860000},"page":"736-743","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Basal subtype of invasive urothelial carcinoma of the bladder has aggressive behavior and poor prognosis: An immunohistochemistry-based study"],"prefix":"10.4103","volume":"68","author":[{"given":"Swetha","family":"Venkatakrishnan","sequence":"first","affiliation":[{"name":"Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree Rekha","family":"Jinkala","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. S.","family":"Sreerag","sequence":"additional","affiliation":[{"name":"Department of Urology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Kayal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"R1-20251208","first-page":"209","article-title":"Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20251208","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer:Summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"R3-20251208","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"R4-20251208","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"R5-20251208","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2214\/AJR.10.5036","article-title":"Metastatic pattern of bladder cancer:Correlation with the characteristics of the primary tumor","volume":"196","author":"Shinagare","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"R6-20251208","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.3390\/ijms21165670","article-title":"Evolution of urothelial bladder cancer in the context of molecular classifications","volume":"21","author":"Minoli","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R7-20251208","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"R8-20251208","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"key":"R9-20251208","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1369\/00221554221095530","article-title":"Immunohistochemical assays for bladder cancer molecular subtyping:Optimizing parsimony and performance of Lund taxonomy classifiers","volume":"70","author":"Hardy","year":"2022","journal-title":"J Histochem Cytochem"},{"key":"R10-20251208","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1038\/modpathol.2009.1","article-title":"Staging and reporting of urothelial carcinoma of urinary bladder","volume":"22","author":"Cheng","year":"2009","journal-title":"Mod Pathol"},{"key":"R11-20251208","doi-asserted-by":"crossref","first-page":"151397","DOI":"10.1016\/j.anndiagpath.2019.08.001","article-title":"Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5\/6, 14 and 20","volume":"43","author":"Jangir","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"R12-20251208","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"R13-20251208","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma:Global mRNA classification versus tumor-cell phenotype classification","volume":"242","author":"Sj\u00f6dahl","year":"2017","journal-title":"J Pathol"},{"key":"R14-20251208","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1073\/pnas.1120605109","article-title":"Three differentiation states risk-stratify bladder cancer into distinct subtypes","volume":"109","author":"Volkmer","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-20251208","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"R16-20251208","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/jclinpath-2021-207573","article-title":"Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression","volume":"75","author":"Olkhov-Mitsel","year":"2022","journal-title":"J Clin Pathol"},{"key":"R17-20251208","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","article-title":"Assessment of luminal and basal phenotypes in bladder cancer","volume":"10","author":"Guo","year":"2020","journal-title":"Sci Rep"},{"key":"R18-20251208","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/15321819.2021.1937212","article-title":"Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5\/6","volume":"42","author":"Serag","year":"2021","journal-title":"J Immunoassay Immunochem"},{"key":"R19-20251208","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.3390\/ijms24076610","article-title":"Clinicopathological features and survival analysis in molecular subtypes of muscle-invasive bladder cancer","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R20-20251208","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","article-title":"A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort","volume":"8","author":"Marzouka","year":"2018","journal-title":"Sci Rep"},{"key":"R21-20251208","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"R22-20251208","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-18-3558","article-title":"Molecular characterization of neuroendocrine-like bladder cancer","volume":"25","author":"Batista","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R23-20251208","doi-asserted-by":"crossref","first-page":"968","DOI":"10.17305\/bb.2023.9242","article-title":"Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5\/6 and p16","volume":"23","author":"Terlevi\u0107","year":"2023","journal-title":"Biomol Biomed"},{"key":"R24-20251208","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00428-022-03361-0","article-title":"Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice","volume":"481","author":"Queipo","year":"2022","journal-title":"Virchows Arch"},{"key":"R25-20251208","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/ijms22020628","article-title":"Comprehensive gene expression analyses of immunohistochemically defined subgroups of muscle-invasive urinary bladder urothelial carcinoma","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R26-20251208","article-title":"CK5\/6 and GATA3 defined phenotypes of muscle-invasive bladder cancer:Impact in adjuvant chemotherapy and molecular subtyping of negative cases","volume":"9","author":"Koll","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R28-20251208","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2015.66.3047","article-title":"Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations","volume":"34","author":"Choudhury","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_290_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:20:26Z","timestamp":1787836826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_290_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_290_25","relation":{},"ISSN":["0377-4929","0974-5130"],"issn-type":[{"value":"0377-4929","type":"print"},{"value":"0974-5130","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"2025-03-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}